First Albany maintains its 'buy' rating on Myriad Genetics, Inc. (Nasdaq: MYGN) on the news that the Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE